Trioxifene mesylate | CAS#68307-81-3 | antiestrogen

MedKoo Cat#: 558449 | Name: Trioxifene mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Trioxifene mesylate is an antiestrogen that inhibits growth hormone secretion.

Chemical Structure

Trioxifene mesylate

CAS#68307-81-3 (mesylate)

Theoretical Analysis

MedKoo Cat#: 558449

Name: Trioxifene mesylate

CAS#: 68307-81-3 (mesylate)

Chemical Formula: C60H64N2O8S

Exact Mass: 972.4400

Molecular Weight: 973.24

Elemental Analysis: C, 74.05; H, 6.63; N, 2.88; O, 13.15; S, 3.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

68307-81-3 (mesylate) 63619-84-1 (free base)

Synonym

Trioxifene mesylate; LY133314; LY-133314; LY 133314;

IUPAC/Chemical Name

Ketone, 3,4-dihydro-2-(p-methoxyphenyl)-1-naphthyl-p-(2-(1-pyrrolidinyl)ethoxy)phenyl, methanesulfonate

InChi Key

DHFAPIZDRMEMLX-UHFFFAOYSA-N

InChi Code

InChI=1S/C59H60N2O5.CH4O3S/c1-63-45-21-15-43(16-22-45)51-27-19-41-11-3-5-13-49(41)57(51)55-39-47(65-37-35-60-31-7-8-32-60)25-29-53(55)59(62)54-30-26-48(66-38-36-61-33-9-10-34-61)40-56(54)58-50-14-6-4-12-42(50)20-28-52(58)44-17-23-46(64-2)24-18-44;1-5(2,3)4/h3-6,11-18,21-26,29-30,39-40H,7-10,19-20,27-28,31-38H2,1-2H3;1H3,(H,2,3,4)

SMILES Code

O=C(C1=CC=C(OCCN2CCCC2)C=C1C3=C(C4=CC=C(OC)C=C4)CCC5=C3C=CC=C5)C6=CC=C(OCCN7CCCC7)C=C6C8=C(C9=CC=C(OC)C=C9)CCC%10=C8C=CC=C%10.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 973.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 1;57(1):40-3. PubMed PMID: 3940620. 2: Arafah B, Manni A, Pearson OH. Trioxifene mesylate (LY 133314): a new antiestrogen which inhibits growth hormone secretion in the rat. Eur J Cancer. 1980;Suppl 1:281-5. PubMed PMID: 7032941. 3: Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ. A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer. 1986 Jan 1;57(1):34-9. PubMed PMID: 3079661. 4: Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA, Jones CD, Krishnan V, Lynch R, Osborne HE, Graff JR. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res. 2003 Sep 15;63(18):6056-62. PubMed PMID: 14522935. 5: Black LJ, Jones CD, Goode RL. Differential interaction of antiestrogens with cytosol estrogen receptors. Mol Cell Endocrinol. 1981 Apr;22(1):95-103. PubMed PMID: 7239000. 6: Rose DP, Fischer AH, Jordan VC. Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas. Eur J Cancer Clin Oncol. 1981 Aug;17(8):893-8. PubMed PMID: 7198978. 7: Black LJ, Goode RL. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci. 1980 Apr 28;26(17):1453-8. PubMed PMID: 7382727. 8: Wakeling AE, Valcaccia B. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. J Endocrinol. 1983 Dec;99(3):455-64. PubMed PMID: 6644236. 9: Castracane VD, Kuehl TJ, Goldzieher JW. The effect of estrogen antagonism on progesterone production in early pregnancy in the baboon (Papio cynocephalus). Am J Obstet Gynecol. 1983 Mar 15;145(6):725-9. PubMed PMID: 6829661. 10: Jones CD, Blaszczak LC, Goettel ME, Suarez T, Crowell TA, Mabry TE, Ruenitz PC, Srivatsan V. Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone. J Med Chem. 1992 Mar 6;35(5):931-8. PubMed PMID: 1548683. 11: Jordan VC, Gosden B. Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol. 1982 Aug;27(3):291-306. PubMed PMID: 7128917. 12: Jordan VC, Gottardis MM, Satyaswaroop PG. Tamoxifen-stimulated growth of human endometrial carcinoma. Ann N Y Acad Sci. 1991;622:439-46. PubMed PMID: 1905895. 13: Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem. 1984 Jan;20(1):111-20. PubMed PMID: 6538611. 14: Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 1990 Jun 1;50(11):3189-92. PubMed PMID: 2334915. 15: Osborne CK, Boldt DH, Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr;44(4):1433-9. PubMed PMID: 6704960. 16: Williams DC, Paul DC, Herring JR. Effects of antiestrogenic compounds on avian medullary bone formation. J Bone Miner Res. 1991 Nov;6(11):1249-56. PubMed PMID: 1805547. 17: Pinney KG, Carlson KE, Katzenellenbogen JA. Nonsteroidal estrogens bearing acyl azide functions: potential electrophilic and photoaffinity labeling agents for the estrogen receptor. Steroids. 1992 May;57(5):222-32. PubMed PMID: 1488784. 18: Izuo M. [New drugs in endocrine treatment of breast cancer]. Nihon Naibunpi Gakkai Zasshi. 1992 May 20;68(5):538-49. Review. Japanese. PubMed PMID: 1322843. 19: Thomas T, Kiang DT. Additive growth-inhibitory effects of DL-alpha-difluoromethylornithine and antiestrogens on MCF-7 breast cancer cell line. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1338-45. PubMed PMID: 3120713. 20: Coradini D, Biffi A, Cappelletti V, Di Fronzo G. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells. Anticancer Res. 1994 May-Jun;14(3A):1059-64. PubMed PMID: 8074450.